We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 17, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Broadcom Inc. (AVGO - Free Report) , Amgen Inc. (AMGN - Free Report) , BlackRock, Inc. (BLK - Free Report) and The Estée Lauder Companies Inc. (EL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Nike, Broadcom and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Broadcom and Amgen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Nike shares have been standout performers, up +107.1% over the past year, as the company benefited from a strong digital push that capitalized on the strength of its brands and investments made over the past several years to improve digital consumer experiences.
Moreover, it started the holiday season on a strong note with record online sales during the Black Friday week. Management expects sequential growth during the fiscal third quarter. However, it is witnessing lower revenues at the wholesale business and NIKE-owned stores.
Higher restructuring costs and continued investments in digital capabilities also acted as headwinds. SG&A expenses are envisioned to grow in low-single digit in fiscal 2021.
Shares of Broadcom have gained +31.5% in the last six months against the Zacks Electronics - Semiconductors industry's gain of +30.4%. The Zacks analyst believes that robust adoption of Wi-Fi 6 in access gateway, and cable DOCSIS 3.1 products bodes well for the company.
Acceleration in 5G deployment, production ramp up and increase in radio frequency (RF) content favors prospects. Synergies from acquisitions of CA and Symantec's enterprise security business are anticipated to boost its presence in infrastructure software vertical.
Further, an upbeat guidance for second quarter of fiscal 2021 on strong uptick in broadband revenues is encouraging. However, weak enterprise demand is likely to affect Brocade revenues and server storage business.
Amgen shares have gained +4.4% over the past three months against the Zacks Biomedical and Genetics industry's loss of -1.9%. The Zacks analyst believes that Amgen's drugs like Prolia, Xgeva, Repatha, Otezla and biosimilars have been driving sales.
However, increasing competition for its legacy products is hurting the same. Amgen is rapidly advancing its innovative pipeline, most notably sotorasib and tezepelumab. Amgen expects several important clinical data readouts from its innovative pipeline in 2021, which could be catalysts for the stock.
Amgen also boasts a strong biosimilars portfolio, which is an important source of revenues. However, pricing and competitive pressure are concerns. Several of Amgen's marketed drugs face increased pricing headwinds in 2021 and continued COVID-19 headwinds.
Other noteworthy reports we are featuring today include BlackRock and Estée Lauder.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights: NIKE, Broadcom, Amgen, BlackRock and Estee Lauder
For Immediate Release
Chicago, IL – March 17, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Broadcom Inc. (AVGO - Free Report) , Amgen Inc. (AMGN - Free Report) , BlackRock, Inc. (BLK - Free Report) and The Estée Lauder Companies Inc. (EL - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Nike, Broadcom and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Nike, Broadcom and Amgen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Nike shares have been standout performers, up +107.1% over the past year, as the company benefited from a strong digital push that capitalized on the strength of its brands and investments made over the past several years to improve digital consumer experiences.
Moreover, it started the holiday season on a strong note with record online sales during the Black Friday week. Management expects sequential growth during the fiscal third quarter. However, it is witnessing lower revenues at the wholesale business and NIKE-owned stores.
Higher restructuring costs and continued investments in digital capabilities also acted as headwinds. SG&A expenses are envisioned to grow in low-single digit in fiscal 2021.
(You can read the full research report on NIKE here >>>)
Shares of Broadcom have gained +31.5% in the last six months against the Zacks Electronics - Semiconductors industry's gain of +30.4%. The Zacks analyst believes that robust adoption of Wi-Fi 6 in access gateway, and cable DOCSIS 3.1 products bodes well for the company.
Acceleration in 5G deployment, production ramp up and increase in radio frequency (RF) content favors prospects. Synergies from acquisitions of CA and Symantec's enterprise security business are anticipated to boost its presence in infrastructure software vertical.
Further, an upbeat guidance for second quarter of fiscal 2021 on strong uptick in broadband revenues is encouraging. However, weak enterprise demand is likely to affect Brocade revenues and server storage business.
(You can read the full research report on Broadcom here >>>)
Amgen shares have gained +4.4% over the past three months against the Zacks Biomedical and Genetics industry's loss of -1.9%. The Zacks analyst believes that Amgen's drugs like Prolia, Xgeva, Repatha, Otezla and biosimilars have been driving sales.
However, increasing competition for its legacy products is hurting the same. Amgen is rapidly advancing its innovative pipeline, most notably sotorasib and tezepelumab. Amgen expects several important clinical data readouts from its innovative pipeline in 2021, which could be catalysts for the stock.
Amgen also boasts a strong biosimilars portfolio, which is an important source of revenues. However, pricing and competitive pressure are concerns. Several of Amgen's marketed drugs face increased pricing headwinds in 2021 and continued COVID-19 headwinds.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we are featuring today include BlackRock and Estée Lauder.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.